| scholarly article | Q13442814 |
| P50 | author | Christopher E Nelson | Q85299050 |
| P2093 | author name string | Craig L Duvall | |
| Samantha M Sarett | |||
| P2860 | cites work | RNA interference trigger variants: getting the most out of RNA for RNA interference-based therapeutics | Q38019046 |
| Delivery systems and local administration routes for therapeutic siRNA. | Q38076344 | ||
| Delivery materials for siRNA therapeutics | Q38154803 | ||
| Liposomal siRNA nanocarriers for cancer therapy | Q38175250 | ||
| Current issues of RNAi therapeutics delivery and development | Q38238806 | ||
| siRNA conjugates carrying sequentially assembled trivalent N-acetylgalactosamine linked through nucleosides elicit robust gene silencing in vivo in hepatocytes | Q38300722 | ||
| Enhanced intracellular uptake and inhibition of NF-kappaB activation by decoy oligonucleotide released from PLGA microspheres | Q38330798 | ||
| Kinetic analysis of the RNAi enzyme complex | Q38340658 | ||
| Development of a sustained-release biodegradable polymer delivery system for site-specific delivery of oligonucleotides: characterization of P(LA-GA) copolymer microspheres in vitro | Q38550543 | ||
| A porous tissue engineering scaffold selectively degraded by cell-generated reactive oxygen species. | Q38609528 | ||
| Topical prolyl hydroxylase domain-2 silencing improves diabetic murine wound closure | Q38808190 | ||
| Hydrogel doped with nanoparticles for local sustained release of siRNA in breast cancer | Q38967041 | ||
| Cancer-specific gene silencing through therapeutic siRNA delivery with B vitamin-based nanoassembled low-molecular-weight hydrogelators. | Q38974352 | ||
| Targetable micelleplex hydrogel for long-term, effective, and systemic siRNA delivery. | Q38982561 | ||
| Tumor targeting RGD conjugated bio-reducible polymer for VEGF siRNA expressing plasmid delivery | Q38988571 | ||
| Patterned substrates of nano-graphene oxide mediating highly localized and efficient gene delivery | Q39011218 | ||
| Hydrogel-nanoparticle composites for optically modulated cancer therapeutic delivery | Q39030709 | ||
| Nanolayered siRNA dressing for sustained localized knockdown | Q39152253 | ||
| An injectable cell penetrable nano-polyplex hydrogel for localized siRNA delivery | Q39180498 | ||
| Injectable polyplex hydrogel for localized and long-term delivery of siRNA. | Q39337569 | ||
| MAD (multiagent delivery) nanolayer: delivering multiple therapeutics from hierarchically assembled surface coatings | Q37726055 | ||
| MK2 inhibitory peptide delivered in nanopolyplexes prevents vascular graft intimal hyperplasia. | Q37727105 | ||
| Bioreducible cationic polymer-based nanoparticles for efficient and environmentally triggered cytoplasmic siRNA delivery to primary human brain cancer cells | Q37731666 | ||
| Selective gene silencing by viral delivery of short hairpin RNA | Q21245112 | ||
| Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8 | Q24310398 | ||
| Overexpression of exportin 5 enhances RNA interference mediated by short hairpin RNAs and microRNAs | Q24324793 | ||
| Lack of p21 expression links cell cycle control and appendage regeneration in mice | Q24600429 | ||
| Introduction of a Chimeric Chalcone Synthase Gene into Petunia Results in Reversible Co-Suppression of Homologous Genes in trans | Q24677038 | ||
| Insights into the kinetics of siRNA-mediated gene silencing from live-cell and live-animal bioluminescent imaging | Q25255924 | ||
| Sustained delivery of siRNAs targeting viral infection by cell-degradable multilayered polyelectrolyte films | Q27487098 | ||
| Origins and Mechanisms of miRNAs and siRNAs | Q27860822 | ||
| Role for a bidentate ribonuclease in the initiation step of RNA interference | Q27860832 | ||
| Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells | Q27860926 | ||
| Single-stranded antisense siRNAs guide target RNA cleavage in RNAi | Q28201784 | ||
| Long-term patency of saphenous vein and left internal mammary artery grafts after coronary artery bypass surgery: results from a Department of Veterans Affairs Cooperative Study | Q28211202 | ||
| Nanotoxicity: a key obstacle to clinical translation of siRNA-based nanomedicine | Q28390007 | ||
| An RNA-directed nuclease mediates post-transcriptional gene silencing in Drosophila cells | Q29547714 | ||
| Expression profiling reveals off-target gene regulation by RNAi | Q29615965 | ||
| Phase 1 dose-escalation study of a siRNA targeting the RTP801 gene in age-related macular degeneration patients | Q30451413 | ||
| Heterozygous deficiency of PHD2 restores tumor oxygenation and inhibits metastasis via endothelial normalization | Q30579125 | ||
| Correlating animal and human phase Ia/Ib clinical data with CALAA-01, a targeted, polymer-based nanoparticle containing siRNA. | Q30837863 | ||
| RNA interference targeting transforming growth factor-beta type II receptor suppresses ocular inflammation and fibrosis. | Q31120024 | ||
| Intravitreal injection of vascular endothelial growth factor small interfering RNA inhibits growth and leakage in a nonhuman primate, laser-induced model of choroidal neovascularization | Q33201362 | ||
| Thermally responsive injectable hydrogel incorporating methacrylate-polylactide for hydrolytic lability | Q33615044 | ||
| In-situ crosslinking hydrogels for combinatorial delivery of chemokines and siRNA-DNA carrying microparticles to dendritic cells | Q33635879 | ||
| RNAi-mediated silencing of hepatic Alas1 effectively prevents and treats the induced acute attacks in acute intermittent porphyria mice | Q33694417 | ||
| First-in-human mutation-targeted siRNA phase Ib trial of an inherited skin disorder. | Q33730680 | ||
| Tuning PEGylation of mixed micelles to overcome intracellular and systemic siRNA delivery barriers. | Q33816969 | ||
| Efficient delivery of small interfering RNA to bone-metastatic tumors by using atelocollagen in vivo. | Q33913718 | ||
| Chitosan hydrogel as siRNA vector for prolonged gene silencing | Q33925196 | ||
| Col V siRNA engineered tenocytes for tendon tissue engineering | Q33945381 | ||
| Catch and Release: Photocleavable Cationic Diblock Copolymers as a Potential Platform for Nucleic Acid Delivery | Q33970635 | ||
| Controlled release for local delivery of drugs: barriers and models | Q34079560 | ||
| Gene delivery by surface immobilization of plasmid to tissue-engineering scaffolds | Q34082344 | ||
| Oncogenic KRAS signalling in pancreatic cancer | Q34113460 | ||
| Ocular neuroprotection by siRNA targeting caspase-2 | Q34192944 | ||
| Device-based local delivery of siRNA against mammalian target of rapamycin (mTOR) in a murine subcutaneous implant model to inhibit fibrous encapsulation | Q34288026 | ||
| Delivery of siRNA therapeutics: barriers and carriers | Q34293708 | ||
| siRNA nanoparticle functionalization of nanostructured scaffolds enables controlled multilineage differentiation of stem cells. | Q34343747 | ||
| In vivo activity of nuclease-resistant siRNAs | Q34365687 | ||
| Exploring polyethylenimine-mediated DNA transfection and the proton sponge hypothesis | Q34367669 | ||
| Non-viral vectors for gene-based therapy | Q34429032 | ||
| Histidine-rich peptides and polymers for nucleic acids delivery | Q34456743 | ||
| Incorporation of active DNA/cationic polymer polyplexes into hydrogel scaffolds | Q34474842 | ||
| Dual pH- and temperature-responsive microparticles for protein delivery to ischemic tissues | Q34583343 | ||
| Cellular and molecular basis of wound healing in diabetes | Q34625159 | ||
| Ocular biodistribution of bevasiranib following a single intravitreal injection to rabbit eyes | Q34656454 | ||
| Conditional deletion of gremlin causes a transient increase in bone formation and bone mass | Q34676851 | ||
| Local applications of myostatin-siRNA with atelocollagen increase skeletal muscle mass and recovery of muscle function | Q34746296 | ||
| Sequence- and target-independent angiogenesis suppression by siRNA via TLR3 | Q34764750 | ||
| Vascular proliferation and atherosclerosis: new perspectives and therapeutic strategies. | Q34986363 | ||
| Chitosan hydrogel for localized gene silencing | Q35001428 | ||
| Development of a novel endosomolytic diblock copolymer for siRNA delivery | Q35031634 | ||
| BMP-2, hypoxia, and COL1A1/HtrA1 siRNAs favor neo-cartilage hyaline matrix formation in chondrocytes | Q35036611 | ||
| An aptamer-siRNA chimera suppresses HIV-1 viral loads and protects from helper CD4(+) T cell decline in humanized mice | Q35111705 | ||
| Hyaluronic acid and fibrin hydrogels with concentrated DNA/PEI polyplexes for local gene delivery | Q35112949 | ||
| Orally delivered thioketal nanoparticles loaded with TNF-α-siRNA target inflammation and inhibit gene expression in the intestines | Q35124399 | ||
| Improved diabetic wound healing through topical silencing of p53 is associated with augmented vasculogenic mediators | Q35133453 | ||
| Modified-chitosan/siRNA nanoparticles downregulate cellular CDX2 expression and cross the gastric mucus barrier | Q35187370 | ||
| Intra-articular delivery of anti-Hif-2α siRNA by chondrocyte-homing nanoparticles to prevent cartilage degeneration in arthritic mice | Q35602634 | ||
| MiRNA inhibition in tissue engineering and regenerative medicine | Q35799937 | ||
| Directing human embryonic stem cell differentiation by non-viral delivery of siRNA in 3D culture | Q35855845 | ||
| Intra-articular controlled release of anti-inflammatory siRNA with biodegradable polymer microparticles ameliorates temporomandibular joint inflammation | Q36194976 | ||
| The silent treatment: siRNAs as small molecule drugs | Q36362370 | ||
| Functionalized, biodegradable hydrogels for control over sustained and localized siRNA delivery to incorporated and surrounding cells | Q36428234 | ||
| Hyaluronic acid/chitosan multilayer coatings on neuronal implants for localized delivery of siRNA nanoplexes | Q39438965 | ||
| Amelioration of psoriasis by anti-TNF-alpha RNAi in the xenograft transplantation model | Q39502368 | ||
| Multivalent cyclic RGD conjugates for targeted delivery of small interfering RNA. | Q39506968 | ||
| Retro-inversion of certain cell-penetrating peptides causes severe cellular toxicity | Q39633042 | ||
| Sustained local delivery of siRNA from an injectable scaffold | Q39641314 | ||
| siRNA Knockdown of Ribonucleotide Reductase Inhibits Melanoma Cell Line Proliferation Alone or Synergistically with Temozolomide | Q39644504 | ||
| Tolerance for mutations and chemical modifications in a siRNA. | Q39698017 | ||
| RNA interference by nanofiber-based siRNA delivery system. | Q39742568 | ||
| Localized and sustained delivery of silencing RNA from macroscopic biopolymer hydrogels. | Q39837392 | ||
| RNA interference for noggin enhances the biological activity of bone morphogenetic proteins in vivo and in vitro | Q39878241 | ||
| Injectable biodegradable polyurethane scaffolds with release of platelet-derived growth factor for tissue repair and regeneration | Q39976454 | ||
| Prolonged gene silencing in hepatoma cells and primary hepatocytes after small interfering RNA delivery with biodegradable poly(beta-amino esters). | Q39983580 | ||
| Efficient in vivo delivery of siRNA to the liver by conjugation of alpha-tocopherol | Q39999051 | ||
| Delivery of siRNA from lyophilized polymeric surfaces | Q40064683 | ||
| Atelocollagen-mediated local and systemic applications of myostatin-targeting siRNA increase skeletal muscle mass | Q40116203 | ||
| Graphene multilayers as gates for multi-week sequential release of proteins from surfaces | Q40127575 | ||
| An siRNA-based microbicide protects mice from lethal herpes simplex virus 2 infection | Q40347915 | ||
| Novel human-derived cell-penetrating peptides for specific subcellular delivery of therapeutic biomolecules | Q40429544 | ||
| DNA delivery from polymer matrices for tissue engineering | Q40945294 | ||
| An in situ gelling liquid crystalline system based on monoglycerides and polyethylenimine for local delivery of siRNAs | Q41281656 | ||
| Tocopheryl oligochitosan-based self assembling oligomersomes for siRNA delivery | Q41617457 | ||
| siRNA function in RNAi: a chemical modification analysis | Q42044356 | ||
| Matrix Metalloproteinase Responsive, Proximity-activated Polymeric Nanoparticles for siRNA Delivery. | Q42077942 | ||
| The Business of RNAi Therapeutics in 2012 | Q42212141 | ||
| Nanofiber-mediated controlled release of siRNA complexes for long term gene-silencing applications. | Q42810537 | ||
| Surface-tethered DNA complexes for enhanced gene delivery | Q42815291 | ||
| Snail1 down-regulation using small interfering RNA complexes delivered through collagen scaffolds | Q42832165 | ||
| Cell protective, ABC triblock polymer-based thermoresponsive hydrogels with ROS-triggered degradation and drug release | Q42835152 | ||
| RNAi-based treatment for neovascular age-related macular degeneration by Sirna-027. | Q42977647 | ||
| Sustained release of vancomycin from polyurethane scaffolds inhibits infection of bone wounds in a rat femoral segmental defect model | Q43103895 | ||
| Dual MMP7-proximity-activated and folate receptor-targeted nanoparticles for siRNA delivery. | Q43105872 | ||
| Photo-cross-linked hydrogels from thermoresponsive PEGMEMA-PPGMA-EGDMA copolymers containing multiple methacrylate groups: mechanical property, swelling, protein release, and cytotoxicity. | Q43277979 | ||
| Smooth muscle cell growth in photopolymerized hydrogels with cell adhesive and proteolytically degradable domains: synthetic ECM analogs for tissue engineering | Q43749607 | ||
| Controlled release of anti-inflammatory siRNA from biodegradable polymeric microparticles intended for intra-articular delivery to the temporomandibular joint | Q44000640 | ||
| Small interfering RNAs mediate sequence-independent gene suppression and induce immune activation by signaling through toll-like receptor 3. | Q44043660 | ||
| Engineering mucosal RNA interference in vivo | Q44055198 | ||
| Development of a functionalized polymer for stent coating in the arterial delivery of small interfering RNA. | Q44313324 | ||
| RNA interference in mammalian cells by chemically-modified RNA. | Q44496696 | ||
| Bioactive coronary stent coating based on layer-by-layer technology for siRNA release | Q44582247 | ||
| Image-based analysis of lipid nanoparticle-mediated siRNA delivery, intracellular trafficking and endosomal escape | Q44591306 | ||
| RNA Interference Therapy in Lung Transplant Patients Infected with Respiratory Syncytial Virus | Q45372948 | ||
| Evaluation of the safety, tolerability and pharmacokinetics of ALN-RSV01, a novel RNAi antiviral therapeutic directed against respiratory syncytial virus (RSV). | Q45397417 | ||
| Protective effect of lentivirus-mediated siRNA targeting ADAMTS-5 on cartilage degradation in a rat model of osteoarthritis | Q45668280 | ||
| In vitro degradation rate of apatitic calcium phosphate cement with incorporated PLGA microspheres. | Q45745627 | ||
| Gene silencing by adenovirus-delivered siRNA. | Q45859505 | ||
| Inhibition of Smad3 expression in radiation-induced fibrosis using a novel method for topical transcutaneous gene therapy | Q45862302 | ||
| Topical matrix-based siRNA silences local gene expression in a murine wound model. | Q45869455 | ||
| Suppression of early experimental osteoarthritis by in vivo delivery of the adenoviral vector-mediated NF-kappaBp65-specific siRNA. | Q45870090 | ||
| Acellular dermal matrix-based gene therapy augments graft incorporation | Q45872958 | ||
| An immobilized nanoparticle-based platform for efficient gene knockdown of targeted cells in the circulation | Q45886326 | ||
| Angiogenic/osteogenic response of BMMSCs on bone-derived scaffold: effect of hypoxia and role of PI3K/Akt-mediated VEGF-VEGFR pathway. | Q45962244 | ||
| Nanofibrous scaffold-mediated REST knockdown to enhance neuronal differentiation of stem cells. | Q45970832 | ||
| 2'-O-(2-Methoxy)ethyl-modified anti-intercellular adhesion molecule 1 (ICAM-1) oligonucleotides selectively increase the ICAM-1 mRNA level and inhibit formation of the ICAM-1 translation initiation complex in human umbilical vein endothelial cells. | Q46002868 | ||
| Safety and efficacy of RNAi therapy for transthyretin amyloidosis | Q46836193 | ||
| Chitosan/siRNA nanoparticles encapsulated in PLGA nanofibers for siRNA delivery. | Q46876859 | ||
| How porosity and size affect the drug release mechanisms from PLGA-based microparticles | Q47348019 | ||
| Vaginal delivery of siRNA using a novel PEGylated lipoplex-entrapped alginate scaffold system. | Q50526871 | ||
| Blockage of Src by Specific siRNA as a Novel Therapeutic Strategy to Prevent Destructive Repair in Steroid-Associated Osteonecrosis in Rabbits. | Q50983781 | ||
| Synthetic dsRNA Dicer substrates enhance RNAi potency and efficacy. | Q51562160 | ||
| Inhibition of Smad3 expression decreases collagen synthesis in keloid disease fibroblasts. | Q51736182 | ||
| ERK2 small interfering RNAs prevent epidural fibrosis via the efficient inhibition of collagen expression and inflammation in laminectomy rats. | Q53068926 | ||
| Comparison of antisense oligonucleotides and siRNAs in cell culture and in vivo. | Q53960627 | ||
| SiRNA-loaded multi-shell nanoparticles incorporated into a multilayered film as a reservoir for gene silencing. | Q54427228 | ||
| Controlled release of NFkappaB decoy oligonucleotides from biodegradable polymer microparticles | Q57188403 | ||
| A novel injectable thermoresponsive and cytocompatible gel of poly( N -isopropylacrylamide) with layered double hydroxides facilitates siRNA delivery into chondrocytes in 3D culture | Q57349439 | ||
| Prolyl hydroxylase inhibitors increase the production of vascular endothelial growth factor by periodontal fibroblasts | Q58942414 | ||
| Layer-by-Layer Assembly of All Carbon Nanotube Ultrathin Films for Electrochemical Applications | Q59791252 | ||
| Polylysine-based transfection systems utilizing receptor-mediated delivery | Q73850333 | ||
| Synthetic TGF-beta antagonist accelerates wound healing and reduces scarring | Q74558114 | ||
| Modulation of scratching behavior by silencing an endogenous cyclooxygenase-1 gene in the skin through the administration of siRNA | Q80805732 | ||
| Topical application of cream-emulsified CD86 siRNA ameliorates allergic skin disease by targeting cutaneous dendritic cells | Q81227736 | ||
| Localized delivery of antisense oligonucleotides by cationic hydrogel suppresses TNF-α expression and endotoxin-induced osteolysis | Q82794580 | ||
| Amino-modified and lipid-conjugated dicer-substrate siRNA enhances RNAi efficacy | Q83210784 | ||
| BSA degradation under acidic conditions: a model for protein instability during release from PLGA delivery systems | Q83856311 | ||
| VEGF therapy: a timely retreat | Q84172986 | ||
| Local delivery of siRNA using a biodegradable polymer application to enhance BMP-induced bone formation | Q85025836 | ||
| Hepatocyte-specific delivery of siRNAs conjugated to novel non-nucleosidic trivalent N-acetylgalactosamine elicits robust gene silencing in vivo | Q86953392 | ||
| Controlling fibrous capsule formation through long-term down-regulation of collagen type I (COL1A1) expression by nanofiber-mediated siRNA gene silencing. | Q36471117 | ||
| Controlled delivery of T-box21 small interfering RNA ameliorates autoimmune alopecia (Alopecia Areata) in a C3H/HeJ mouse model. | Q36482238 | ||
| Biomimetic materials for tissue engineering | Q36502929 | ||
| The effect of combined IL10 siRNA and CpG ODN as pathogen-mimicking microparticles on Th1/Th2 cytokine balance in dendritic cells and protective immunity against B cell lymphoma | Q36561226 | ||
| Cell penetrating peptides: intracellular pathways and pharmaceutical perspectives | Q36795351 | ||
| Matrices and scaffolds for DNA delivery in tissue engineering | Q36826532 | ||
| Regulation and guidance of cell behavior for tissue regeneration via the siRNA mechanism. | Q36835045 | ||
| Interfering with disease: a progress report on siRNA-based therapeutics | Q36836598 | ||
| Durable knockdown and protection from HIV transmission in humanized mice treated with gel-formulated CD4 aptamer-siRNA chimeras | Q36984469 | ||
| Synthesis and fabrication of a degradable poly(N-isopropyl acrylamide) scaffold for tissue engineering applications | Q37016788 | ||
| Overcoming the innate immune response to small interfering RNA. | Q37071130 | ||
| Plasmid delivery in vivo from porous tissue-engineering scaffolds: transgene expression and cellular transfection | Q37110938 | ||
| Biodegradable polyurethanes: synthesis and applications in regenerative medicine | Q37153739 | ||
| Intravaginal gene silencing using biodegradable polymer nanoparticles densely loaded with small-interfering RNA | Q37219628 | ||
| Enhancing microvascular formation and vessel maturation through temporal control over multiple pro-angiogenic and pro-maturation factors. | Q37262654 | ||
| Connective tissue growth factor: growth factor, matricellular organizer, fibrotic biomarker or molecular target for anti-fibrotic therapy in SSc? | Q37265882 | ||
| Antisense makes sense in engineered regenerative medicine | Q37328072 | ||
| Chemical modification of siRNAs for in vivo use. | Q37331765 | ||
| siRNA conjugate delivery systems | Q37340480 | ||
| Balancing cationic and hydrophobic content of PEGylated siRNA polyplexes enhances endosome escape, stability, blood circulation time, and bioactivity in vivo | Q37378292 | ||
| Knocking down barriers: advances in siRNA delivery | Q37380671 | ||
| Triple combination of siRNAs targeting TGFβ1, TGFβR2, and CTGF enhances reduction of collagen I and smooth muscle actin in corneal fibroblasts. | Q37401564 | ||
| Mutant KRAS is a druggable target for pancreatic cancer | Q37409321 | ||
| Regulation of oxygen homeostasis by hypoxia-inducible factor 1. | Q37443475 | ||
| Complexity in biomaterials for tissue engineering. | Q37490816 | ||
| Molecularly self-assembled nucleic acid nanoparticles for targeted in vivo siRNA delivery | Q37504038 | ||
| Gene silencing in human aortic smooth muscle cells induced by PEI-siRNA complexes released from dip-coated electrospun poly(ethylene terephthalate) grafts | Q37593277 | ||
| Lipidic systems for in vivo siRNA delivery | Q37598096 | ||
| Non-viral DNA delivery from porous hyaluronic acid hydrogels in mice | Q37615651 | ||
| Tunable staged release of therapeutics from layer-by-layer coatings with clay interlayer barrier | Q37633656 | ||
| Tunable delivery of siRNA from a biodegradable scaffold to promote angiogenesis in vivo. | Q37633993 | ||
| Recognizing and avoiding siRNA off-target effects for target identification and therapeutic application | Q37665303 | ||
| Phase I clinical trial of SYL040012, a small interfering RNA targeting β-adrenergic receptor 2, for lowering intraocular pressure | Q37690494 | ||
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 94-113 | |
| P577 | publication date | 2015-11-01 | |
| P1433 | published in | Journal of Controlled Release | Q6295046 |
| P1476 | title | Technologies for controlled, local delivery of siRNA | |
| P478 | volume | 218 |
| Q92219048 | Applications of RNA interference in the treatment of arthritis |
| Q37394496 | Chaperonin-Dendrimer Conjugates for siRNA Delivery. |
| Q47378147 | Codelivery of sorafenib and GPC3 siRNA with PEI-modified liposomes for hepatoma therapy |
| Q57564390 | Composite vector formulation for multiple siRNA delivery as a host targeting antiviral in a cell culture model of hepatitis C virus (HCV) infection |
| Q47160679 | Delivery Pathway Regulation of 3′,3″-Bis-Peptide-siRNA Conjugate via Nanocarrier Architecture Engineering |
| Q39038930 | Engineered Hydrogels for Local and Sustained Delivery of RNA-Interference Therapies. |
| Q40064209 | HuR-targeted small molecule inhibitor exhibits cytotoxicity towards human lung cancer cells. |
| Q26741449 | Lipid nanoparticles for targeted siRNA delivery - going from bench to bedside |
| Q42856140 | Local Delivery of PHD2 siRNA from ROS-Degradable Scaffolds to Promote Diabetic Wound Healing |
| Q58735813 | Recent advances in "smart" delivery systems for extended drug release in cancer therapy |
| Q45872562 | Recent advances in exosome-based nanovehicles as RNA interference therapeutic carriers. |
| Q38713376 | Strategies to optimize siRNA delivery to hepatocellular carcinoma cells. |
| Q52671014 | While it is not deliberate, much of today's biomedical research contains logical and technical flaws, showing a need for corrective action. |
Search more.